Edwards Lifesciences Corporation · NYSE (us_market)
Healthcare · Medical Devices · United States
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-07-10$93.78 RISE2024-11-06$65.75 PEAK2024-12-26$75.92 169d | -29.9% 119d | 2024-07-31 $63.05 | 2024-12-26 $75.92 | 63Quality on Sale | 72Deep Value | +15.5% 50d | +20.4% Held 148d |
DROP2024-07-10$93.78 RISE2024-10-07$64.54 PEAK2024-12-26$75.92 169d | -31.2% 89d | 2024-07-31 $63.05 | 2024-12-26 $75.92 | 63Quality on Sale | 72Deep Value | +17.6% 80d | +20.4% Duplicate trade Held 148d |
DROP2024-03-28$95.56 RISE2024-07-25$59.70 PEAK2024-08-22$71.30 147d | -37.5% 119d | 2024-07-29 $63.74 | 2024-08-22 $71.30 | 61Quality on Sale | 57Watch | +19.4% 28d | +11.9% Held 24d |
DROP2023-06-30$94.33 RISE2023-10-27$61.71 PEAK2023-12-14$77.76 167d | -34.6% 119d | Missed | Missed | — | — | +26.0% 48d | Missed |
DROP2022-07-28$107.29 RISE2022-11-04$68.54 PEAK2023-02-02$84.51 189d | -36.1% 99d | 2022-10-17 $85.49 | 2023-02-02 $84.51 | 60Quality on Sale | 57Quality on Sale | +23.3% 90d | -1.1% Held 108d |
DROP2022-04-20$128.27 RISE2022-06-14$86.50 PEAK2022-07-28$107.29 99d | -32.6% 55d | Missed | Missed | — | — | +24.0% 44d | Missed |
DROP2021-12-31$129.55 RISE2022-05-11$93.27 PEAK2022-07-28$107.29 209d | -28.0% 131d | Missed | Missed | — | — | +15.0% 78d | Missed |
DROP2021-12-30$130.68 RISE2022-03-08$102.00 PEAK2022-04-20$128.27 111d | -21.9% 68d | Missed | Missed | — | — | +25.8% 43d | Missed |
DROP2021-12-30$130.68 RISE2022-01-27$101.96 PEAK2022-04-20$128.27 111d | -22.0% 28d | Missed | Missed | — | — | +25.8% 83d | Missed |
DROP2020-09-02$87.44 RISE2020-10-30$71.69 PEAK2020-12-31$91.23 120d | -18.0% 58d | Missed | Missed | — | — | +27.3% 62d | Missed |
DROP2020-01-22$81.00 RISE2020-03-23$52.41 PEAK2020-06-08$76.95 138d | -35.3% 61d | Missed | Missed | — | — | +46.8% 77d | Missed |
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wondering if Edwards Lifesciences at around US$86.51 is offering good value today, or if the recent share price leaves little margin for error. The stock has returned 4.3% over the last week, 3.7% over the past month, 1.4% year to date, and 12.8% over the past year, while the 3 year return sits at 2.7% and the 5 year return shows a decline of 7.4%. Recent coverage has focused on Edwards Lifesciences as a key player in medical equipment, with attention on how its products fit into long term...
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
PARIS & DALLAS, May 18, 2026--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study.
SANTA CLARA, Calif., May 18, 2026--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer.
While Edwards Lifesciences has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
While Edwards Lifesciences has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Soft earnings didn't appear to concern Edwards Lifesciences Corporation's ( NYSE:EW ) shareholders over the last week...
Soft earnings didn't appear to concern Edwards Lifesciences Corporation's ( NYSE:EW ) shareholders over the last week...
Edwards Lifesciences Corporation (EW) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDTCompany ParticipantsBernard Zovighian - CEO...
Presenter SpeechTravis Steed Next up, we have Edwards Life Sciences. Welcome, Bernard.Presenter SpeechBernard Zovighian Thank you.Presenter SpeechTravis Steed Thanks for coming.Presenter
Boston Scientific Corporation outlook: EP share loss vs PFA leadership, Watchman & neuromod growth, improving margins and low valuation. Click for more on BSX.
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, […]
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, […]
Mistras, who joins the heart valve company after two years as CFO at pharmaceutical firm Viatris, also brings investment banking experience.
Mistras, who joins the heart valve company after two years as CFO at pharmaceutical firm Viatris, also brings investment banking experience.
IRVINE, Calif., May 04, 2026--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora ("Doretta") Mistras as the company’s corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role.
Over the past year, many Edwards Lifesciences Corporation ( NYSE:EW ) insiders sold a significant stake in the company...
Over the past year, many Edwards Lifesciences Corporation ( NYSE:EW ) insiders sold a significant stake in the company...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| EW | +2.96% | -0.81% | +1.43% | +10.55% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.00% | +4.90% | +4.87% | -2.14% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 26.30M | $2.11B | 0.07% | Added+1.2% | 2026-03-31 |
| Wellington | fundamental | 22.01M | $1.76B | 0.33% | Added+1.0% | 2026-03-31 |
| FidelityFMR | fundamental | 14.50M | $1.16B | 0.06% | Trimmed-12.5% | 2026-03-31 |
| Citadel | multi-strat | 1.83M | $146.27M | 0.19% | Added+311.0% | 2026-03-31 |
| Viking | long/short | 1.10M | $87.89M | 0.25% | New | 2026-03-31 |
| TwoSigma | quant | 1.05M | $84.21M | 0.07% | Added+168.7% | 2026-03-31 |
| Bridgewater | macro | 171.9K | $13.77M | 0.06% | Added+124.0% | 2026-03-31 |
| RenTech | quant | 29.0K | $2.32M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 4.09M | $327.61K | 0.04% | Added+92.4% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | Dahl Andrew M. | SVP, Corporate Controller | S Open-market sale | 568 | $86.08 | −$48.9K |
| 2026-05-27 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S Open-market sale | 23,145 | $86.42 | −$2.00M |
| 2026-05-22 | Chopra Daveen | CVP, TMTT & Surgical | S Open-market sale | 1,500 | $84.60 | −$126.9K |
| 2026-05-18 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S Open-market sale | 8,000 | $81.82 | −$654.6K |
| 2026-05-18 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S Open-market sale | 9,968 | $82.07 | −$818.1K |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | M Option exercise(deriv) | 620 | — | +$0 |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | S Open-market sale | 620 | $81.14 | −$50.3K |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | M Option exercise | 620 | $72.68 | +$45.1K |
| 2026-05-12 | Chopra Daveen | CVP, TMTT & Surgical | M Option exercise(deriv) | 13,583 | — | +$0 |
| 2026-05-12 | Chopra Daveen | CVP, TMTT & Surgical | F Tax withholding | 7,538 | $79.96 | −$602.7K |
| 2026-05-12 | Chopra Daveen | CVP, TMTT & Surgical | M Option exercise | 13,583 | — | +$0 |
| 2026-05-12 | BOBO DONALD E JR | CVP,Strategy/Corp Development | M Option exercise(deriv) | 13,457 | — | +$0 |
| 2026-05-12 | BOBO DONALD E JR | CVP,Strategy/Corp Development | F Tax withholding | 7,469 | $79.96 | −$597.2K |
| 2026-05-12 | BOBO DONALD E JR | CVP,Strategy/Corp Development | M Option exercise | 13,457 | — | +$0 |
| 2026-05-11 | Lippis Daniel J. | CVP, TAVR | F Tax withholding | 362 | $79.96 | −$28.9K |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | A Grant / award(deriv) | 5,200 | — | +$0 |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | A Grant / award(deriv) | 26,400 | — | +$0 |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | S Open-market sale | 593 | $79.73 | −$47.3K |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | F Tax withholding | 226 | $82.76 | −$18.7K |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | F Tax withholding | 264 | $83.20 | −$22.0K |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | A Grant / award | 5,200 | — | +$0 |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | M Option exercise(deriv) | 19,830 | — | +$0 |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | F Tax withholding | 11,004 | $79.96 | −$879.9K |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | M Option exercise | 19,830 | — | +$0 |
| 2026-05-08 | Bruls Annette | CVP, EMEACLA | A Grant / award(deriv) | 6,650 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-23upcoming | 0.74 | — | — |
| 2026-04-23 | 0.73 | 0.78 | +7.33% |
| 2026-02-10 | 0.62 | 0.58 | -6.27% |
| 2025-10-30 | 0.59 | 0.67 | +12.63% |
| 2025-07-24 | 0.62 | 0.67 | +7.64% |
| 2025-04-23 | 0.60 | 0.64 | +7.46% |
| 2025-02-11 | 0.55 | 0.59 | +6.39% |
| 2024-10-24 | 0.54 | 5.13 | +854.95% |
| 2024-07-24 | 0.69 | 0.70 | +0.88% |
| 2024-04-25 | 0.64 | 0.66 | +2.79% |
| 2024-02-06 | 0.64 | 0.64 | +0.16% |
| 2023-10-25 | 0.59 | 0.59 | -0.66% |
| 2023-07-26 | 0.65 | 0.66 | +1.89% |
| 2023-04-26 | 0.61 | 0.62 | +2.02% |
| 2023-01-31 | 0.61 | 0.64 | +4.51% |
| 2022-10-27 | 0.62 | 0.61 | -2.03% |